Connect with us

Technology

Headlands Research – Summit Portland Celebrates 50 Years of Advancing Alzheimer’s and CNS Clinical Research

Published

on

Headlands Research site marks five decades in Portland, Oregon, having contributed to clinical trials behind every FDA-approved class of Alzheimer’s medication brought to market since 1993

PORTLAND, Ore., Oct. 6, 2026 /PRNewswire/ — Headlands Research – Summit Portland, a Headlands Research site and medical research organization serving the greater Portland, Oregon area, is celebrating its 50th anniversary in 2026. Since its founding in 1976, Headlands Summit has partnered with pharmaceutical companies to advance the development of new medical treatments across a range of psychiatric, neurological, and other health conditions—including a role in the clinical research behind every FDA-approved class of Alzheimer’s disease medication to date.

“Headlands Summit’s fifty years of history and its role in the development of every FDA-approved Alzheimer’s therapy have created a legacy of impact on the health and well-being of patients, families, and caregivers impacted by this disease,” said Kyle Burtnett, CEO of Headlands Research. “Dr. Scott Losk and the Summit team have been committed to that work through every phase of this disease’s treatment history, from the first approved therapy to today’s anti-amyloid antibodies. That kind of scientific commitment drives medical innovation that improves lives, and it’s what sponsors look for in a partner of choice.”

Over five decades, Headlands Summit has evolved alongside the clinical research industry while maintaining a focus on helping bring better treatment options to patients. Today, the site conducts studies across mental health and central nervous system (CNS) conditions, as well as vaccines, diabetes, obesity and weight loss, and other cardiometabolic diseases. Headlands Summit’s capabilities have grown to include the Memory Health Center within Headlands Summit, a dedicated program focused on dementia and other age-related memory conditions.

Dr. Scott Losk, a clinical psychologist and neuropsychologist, has practiced at Headlands Summit since 1990. He has served as a principal investigator on more than 75 clinical trials in Alzheimer’s disease and other dementias and as a sub-investigator on more than 150 clinical trials evaluating treatments for other central nervous system disorders, including depression, anxiety disorders, ADHD, bipolar disorder, schizophrenia, migraine, and fibromyalgia. Throughout his career, Dr. Losk and the Headlands Summit team have contributed to clinical research supporting every FDA-approved class of Alzheimer’s disease medication brought to market since 1993, including acetylcholinesterase inhibitors (tacrine, donepezil, rivastigmine and galantamine), the NMDA receptor antagonist memantine, and anti-amyloid therapies (aducanumab, lecanemab and donanemab).

“Since our founding, our team has remained focused on helping advance research that can improve the lives of patients and families,” said Dr. Losk. “We’re proud of the role Headlands Summit has played across nearly every era of Alzheimer’s drug development, and we’re excited about our current work in burgeoning therapeutic areas.”

“Our team is committed to bringing new research opportunities and potential treatment options to the Portland community,” said Dr. Andre Barkhuizen, Principal Investigator at Headlands Summit. “That means continuing to innovate in the CNS space while also advancing research in new therapeutic areas, including diabetes, obesity and weight loss, and vaccines.”

About Headlands Research – Summit Portland

Headlands Research – Summit Portland, based in Portland, Oregon, is a leading clinical research organization with nearly five decades of experience advancing medical innovation. Since 1976, the site has conducted more than 500 clinical trials in partnership with pharmaceutical companies and CROs. With a dedicated Memory Health Center and deep expertise in psychiatry, dementia, age-related memory issues, and a broad range of other health conditions, Headlands Research – Summit Portland provides clinical trial opportunities for all age groups, including adolescents, adults, and older adults. The site delivers high-quality, participant-centered research and is committed to developing better treatments and improving future health outcomes while maintaining the highest standards of care and compliance.

About Headlands Research

Headlands Research is a leading clinical trial site network with a mission to improve lives by advancing innovative medical therapies. Its group of exceptional sites focuses on large-volume recruitment of diverse and specialty participant populations while delivering the highest quality data. Headlands Research’s principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse participants through its site databases and physician partnerships, Headlands Research has successfully completed more than 5,000 clinical trials. Additional information about the company is available at www.headlandsresearch.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/headlands-research—summit-portland-celebrates-50-years-of-advancing-alzheimers-and-cns-clinical-research-302898963.html

SOURCE Headlands Research

Continue Reading

Technology

Optro Establishes UAE Hub to Support Rapid Transition to Agentic GRC Across the Middle East

Published

on

By

Expansion comes as UAE government mandates transition to Agentic AI models, driving demand for continuous assurance and autonomous risk governance.

DUBAI, UAE, Oct. 6, 2026 /PRNewswire/ — Optro, the leading AI-powered GRC Intelligence Platform, today announced its expansion into the United Arab Emirates (UAE), establishing Dubai as the company’s newest regional center. The move represents a major step forward in serving global GRC teams and providing localized support for its rapidly growing customer base across the Middle East and North Africa (MENA) region. The announcement was made at the 2026 CAE Conference in Abu Dhabi, United Arab Emirates.

The expansion comes at a historic inflection point for technology governance in the region. Under the “UAE Government 4.0” directive of the UAE National Strategy for Artificial Intelligence 2031, federal institutions are tasked with converting 50 percent of government sectors, services, and operations to autonomous Agentic AI models within a two-year timeline. As non-human agents gain authority to execute workflows, invoke APIs, and issue binding administrative decisions, enterprise and public-sector audit, risk, compliance, and infosec teams are facing unprecedented operational, cybersecurity, and regulatory complexities.

With strict regulatory frameworks taking shape, including Central Bank of the UAE (CBUAE) AI & ML Guidance, the UAE National AI Policy & Ethics guidelines, the Federal Personal Data Protection Law (PDPL), and Cybersecurity Council/NESA standards, demand is surging for connected, real-time approaches to audit, risk management, data sovereignty, and non-human access control. Optro is built specifically for this paradigm shift. By deploying agentic AI tailored to regional frameworks, Optro gives local practitioners an unmatched ability to execute continuous risk assessments, manage non-human access identities, and automate live compliance mapping against evolving UAE regulations.

“Enterprises and public sector organizations across the Middle East are setting a global benchmark for autonomous innovation,” said Raul Villar Jr., Chief Executive Officer at Optro. “However, deploying agentic AI at scale requires a corresponding evolution in control and assurance. By establishing our regional hub in the UAE, we are delivering the localized presence, partner network, and agentic GRC tools required to help organizations govern autonomous operations, protect data sovereignty, and turn regulatory compliance into a competitive advantage.”

“Internal Audit and GRC functions are playing an increasingly strategic role in helping organizations strengthen resilience, enhance governance, and respond to emerging risks,” said Fady Nader, EY MENA Risk Consulting Partner. “As organizations continue to embrace digital transformation and AI-enabled ways of working, there is a growing need for integrated assurance and timely risk insights. We are pleased to collaborate with Optro in supporting organizations across the region as they evolve their governance, risk and assurance capabilities and adapt to an increasingly dynamic business environment.”

“Our alliance with Optro reflects Deloitte’s commitment to helping clients modernise their control environments,” said James Smith, Controls Assurance Leader at Deloitte Middle East. “Optro’s investment in regional data hosting is another important step and demonstrates their long-term commitment to the region and we are proud to partner with them.”

Optro’s expansion into the UAE follows the company’s recent launch of its Asia-Pacific (APAC) regional hub in Singapore, announced at The Institute of Internal Auditors (IIA) International Conference in June. Earlier this year, Optro also acquired Midship — the premier AI-native autonomous controls testing solution — delivering highly governed, enterprise-grade AI agents to Optro’s customers and prospects, enabling Optro to rapidly scale across global innovation centers, helping risk, compliance, and audit teams modernize operations and navigate complex regulatory environments in real time.

To learn more about how Optro is transforming risk into opportunity for companies around the world, visit optro.ai.

About Optro 

Optro (formerly AuditBoard) helps enterprises transform risk into opportunity through its AI-powered GRC Intelligence Platform. More than 50% of the Fortune 500 trust Optro to elevate audit, risk, and compliance in addressing a new era of risk. Optro is top-rated by customers on G2 and was named a Leader in the 2025 Gartner® Magic Quadrant™ for Governance, Risk and Compliance (GRC) Tools, Assurance Leaders. To learn more, visit optro.ai.

Media Contact
Laura Groshans
press@optro.ai

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/optro-establishes-uae-hub-to-support-rapid-transition-to-agentic-grc-across-the-middle-east-302899185.html

Continue Reading

Technology

Alchemist Group strengthens technology leadership with appointment of fractional CISO

Published

on

By

LONDON, Oct. 6, 2026 /PRNewswire/ — Alchemist Group, the parent company behind a portfolio of sales and leadership development brands, has appointed former military cyber-specialist James Griffiths as fractional Chief Information Security Officer (CISO) and Chief Technology Officer (CTO) as it continues to invest in proprietary technology designed to enhance learner experiences.

Bringing over 25 years’ experience across cyber-security, technology and digital transformation, including 17 years in the British Army’s Royal Corps of Signals, Griffiths will provide expertise across technology, cyber-security and digital strategy. His appointment will support the Group’s ongoing technology development while ensuring its systems and data remain secure as the business grows.

Following his military career, Griffiths helped deliver cyber-offensive capabilities for UK government organisations including the Ministry of Defence and GCHQ. He later co-founded Cyber Security Associates, scaling the business from a two-person start-up to a £15 million-plus operation with over 100 employees. He’s now founder of technology consultancy UtopianKnight. 

He joins Alchemist Group as the business builds on the recent launch of its Global Product and Technology function. The new division combines research, human expertise, product design and technology to develop learning systems for global organisations facing increasing pressure to improve performance while adapting to rapid advances in AI and workforce capability.

The function supports the Group’s three brands: Alchemist, a leadership development company; RAIN Group, a sales training specialist; and PCA Law, which provides leadership and business development training for legal professionals.

Appointing Griffiths on a fractional basis has also allowed the Group to bring in senior technology and cyber-security expertise without the lead time associated with a permanent hire.

Will Daniel, global vice president of product and technology at Alchemist Group, said: “As we continue investing in our product and technology capabilities, having the right expertise around us is critical. James brings a wealth of experience across technology and cyber-security, as well as a strategic understanding of how those areas need to support wider business objectives.”

Griffiths added: “Alchemist Group has a clear vision for the role technology can play in enhancing the development and delivery of its learning solutions and client experience, making a robust technology and cyber-security approach essential. I’m delighted to be supporting the Group at such an exciting stage in its growth, helping to align technology, security and business priorities to drive innovation, resilience and long-term success.”

View original content:https://www.prnewswire.co.uk/news-releases/alchemist-group-strengthens-technology-leadership-with-appointment-of-fractional-ciso-302898528.html

Continue Reading

Technology

REGENESYS ANNOUNCES BOOST SCHEDULER TO ENHANCE LINKEDIN CONTENT

Published

on

By

The New Service is the Only Scheduling Tool Available to Optimize Post Performance

SAN FRANCISCO, Oct. 6, 2026 /PRNewswire/ — Regenesys, the company that is revolutionizing LinkedIn content distribution has just announced its newest Saas tool – Boost Scheduler – which is an affordable way that allows anyone to schedule boosts for their LinkedIn content. This is an effective tool for brand awareness, trust which also increases reach, followers, profile views and LinkedIn search engine optimization (SEO) to appear at the top of searches.

Boost Scheduler allows users to select the time they wish to publish and is simple and safe to use, a great tool for agencies and social media managers. Many of their clients use this for sales, go-to-market, to meet investors, thought leadership, when exiting their company, or looking for better job opportunities.

Evan Chi, Founder and CEO of Regenesys, said, “Boost Scheduler provides the biggest bang for your buck in terms of LinkedIn performance. There is no other way to solve distribution for content besides paid ads. Our infrastructure removes the ‘luck’ element from LinkedIn. We ensure your most important content gets the eyes it deserves. If you subscribe to Post Booster, you stop leaving your company’s posts to chance. The top 1% of LinkedIn creators are using Regenesys Boost Scheduler to dominate their niche.”

“Before working with Regenesys, our LinkedIn presence was essentially a static resume. By leveraging their post-boosting technology and PR strategies, they completely unlocked our content distribution, helping us turn visibility into a predictable driver of new business. The level of inbound lead generation and profile views we’re seeing now has completely transformed how we acquire clients and grow our pipeline,” said Ryan Baird, CEO of cross border neo-investment bank Baird Augustine.

Evan Chi has also just revamped the Regenesys.io website. He will next launch Regenesys Intelligence, which will be the AI engine for social and competitor intelligence. Regenesys Intelligence will map and score your prospects’ contextual intent against your Ideal Customer Profile (ICP) to surface warm signals and build predictable pipelines.

To further enhance a person or company’s posts, Regenesys also created Omniposte (Omniposte.com), which creates and distributes content across up to 13 social platforms effortlessly. 

About Regenesys

Regenesys has created a LinkedIn system that converts attention to clients more effectively than competing services. It specializes in tools that organically amplify your LinkedIn growth. The company utilizes AI and Social Intelligence to map and score prospects against Ideal Customer Profiles (ICP). Regenesys ensures that content reaches a qualified audience and automates outreach and lead generation.

Media Contact:

Frank Tortorici

frank@marketingmaven.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenesys-announces-boost-scheduler-to-enhance-linkedin-content-302899326.html

SOURCE Regenesys

Continue Reading

Trending